Physiomics PLC
PYC
Company Profile
Business description
Physiomics PLC is a United Kingdom-based firm providing services to pharmaceutical companies through outsourced systems and computational biology. The company is mainly engaged in the development of models to streamline the drug discovery and development process. It focuses to transform oncology drug development. The company operates in the UK, European Union Switzerland and USA.
Contact
140 Eastern Avenue
Bee House, Milton Park
OxfordshireOX14 4SB
GBRT: +44 1235841575
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
7
Stocks News & Analysis
stocks
Wildly overvalued ASX stock is skating on thin ice
This company dominates its industry and could be flirting with regulatory intervention.
stocks
Uber flexes its network effect and delivers strong result
Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.00 | 9.10 | -0.10% |
| CAC 40 | 7,725.15 | 90.12 | 1.18% |
| DAX 40 | 24,317.84 | 393.48 | 1.64% |
| Dow JONES (US) | 44,193.12 | 81.38 | 0.18% |
| FTSE 100 | 9,138.49 | 25.82 | -0.28% |
| HKSE | 25,081.63 | 171.00 | 0.69% |
| NASDAQ | 21,169.42 | 252.87 | 1.21% |
| Nikkei 225 | 41,059.15 | 264.29 | 0.65% |
| NZX 50 Index | 12,887.10 | 6.94 | 0.05% |
| S&P 500 | 6,345.06 | 45.87 | 0.73% |
| S&P/ASX 200 | 8,831.40 | 12.30 | -0.14% |
| SSE Composite Index | 3,639.67 | 5.67 | 0.16% |